G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib

- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding...

Related Keywords

Japan ,Boston ,Massachusetts ,United States ,China ,Genor Biopharma ,Samantha Dale Strasser ,Jack Bailey ,Caitlin Brown ,Research Triangle Park ,Merck Digital Sciences Studio ,Exchange Commission ,Head Of Business Development ,Corporate Communications ,Nasdaq ,Gain Exclusive Rights For The Clinical Development ,National Medical Products Administration ,Linkedin ,Therapeutics Inc ,Gain Exclusive Rights ,Clinical Development ,Regulatory Submissions ,Pepper Bio ,Chief Executive Officer ,Silverton Partners ,Chief Science Officer ,Private Securities Litigation Reform Act ,Bio Contact ,Investor Relations ,Markets ,